A. Haloperidol decanoate B. Olanzapine pamoate C. Risperidone microspheres D. Paliperidone palmitate

A. Fatty acid esterification to create a depot with slow dissolution B. Creation of a molecular entity with very slow hepatic elimination C. Creation of a nanocrystal that undergoes a very slow dissolution D. A and C E. All of the above

A. Identifying patient barriers to use of LAIs, and target information to these barriers B. Facilitating the administration of LAIs through pharmacy-based injection clinic C. Coordinating home health agency-administered LAI antipsychotics to avoid transportation issues D. A and B E. All of the above

A. Haloperidol B. Quetiapine C. Risperidone D. Olanzapine E. Paliperidone

A. All evidence unilaterally supports an advantage over oral formulations B. Randomized trials do not agree on benefits, but epidemiological studies more consistently display benefits for LAI formulations C. All evidence points toward equal rates of relapse and hospitalization for both forms D. Many patients relapse due to the pain of injection associated with LAIs E. Because LAIs require hospitalization to administer, evidence reducing hospitalization is irrelevant

A. Prescriber unfamiliarity with available formulations B. Perceptions regarding increased cost C. Lack of clinical guidelines supporting their use D. A and B E. B and C

A. MI presents the patient with all available information and then asks them what questions they have B. MI presents the patient with information regarding the most common stumbling blocks regarding a decision C. MI allows patients to first voice their concerns, and then the clinician addresses the patient's specific concern D. MI builds rapport by making the clinician appear very knowledgeable about the topic, so the patient will just agree

A. Apologetic B. Authoritarian C. Knowledgeable D. Empathetic E. Paternal

A. Reflect and reinforce the change talk B. Repeating what the patient said and nod C. Impose a conclusion while the time is ripe D. Conclude the interview, before the patient can change his/her mind E. Move on to the next concern

A. Stigma associated with use B. Prescriber unfamiliarity with LAI products C. Cost of products D. Patients are highly adherent with oral therapy E. Availability of products